Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

STOK

Stoke Therapeutics Inc

Sep 12 • 04:00PM ET

23.46

-0.42 -1.76 %

Healthcare • Biotechnology • USA • NASD

Peers: SRPT PTCT FOLD RARE NTLA CRSP EDIT ARWR VRTX ALNY

| Held by: IWM VTI XBI IWO IBB VXF SCHA JSMD JSML DFAC

Scroll to Statements

Index	RUT	P/E	27.76	EPS (ttm)	0.84	Insider Own	16.06%	Shs Outstand	54.72M	Perf Week	13.44%
Market Cap	1.29B	Forward P/E	-	EPS next Y	-2.82	Insider Trans	-26.63%	Shs Float	46.00M	Perf Month	38.73%
Enterprise Value	1.04B	PEG	-	EPS next Q	-0.58	Inst Own	112.46%	Short Float	23.34%	Perf Quarter	98.48%
Income	52.48M	P/S	6.43	EPS this Y	116.69%	Inst Trans	12.30%	Short Ratio	13.28	Perf Half Y	189.27%
Sales	199.89M	P/B	3.83	EPS next Y	-1122.44%	ROA	15.16%	Short Interest	10.74M	Perf YTD	112.69%
Book/sh	6.12	P/C	5.19	EPS next 5Y	-15.71%	ROE	18.17%	52W High	24.00 -2.25%	Perf Year	47.36%
Cash/sh	4.52	P/FCF	21.02	EPS past 3/5Y	10.98% 1.74%	ROIC	15.61%	52W Low	5.35 338.50%	Perf 3Y	56.61%
Dividend Est.	-	EV/EBITDA	23.33	Sales past 3/5Y	- -	Gross Margin	97.82%	Volatility	7.48% 6.33%	Perf 5Y	-18.49%
Dividend TTM	-	EV/Sales	5.21	EPS Y/Y TTM	140.98%	Oper. Margin	20.15%	ATR (14)	1.22	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.98	Sales Y/Y TTM	1218.82%	Profit Margin	26.26%	RSI (14)	82.48	Recom	1.18
Dividend Gr. 3/5Y	- -	Current Ratio	6.98	EPS Q/Q	12.67%	SMA20	15.97%	Beta	1.23	Target Price	24.22
Payout	-	Debt/Eq	0.01	Sales Q/Q	186.01%	SMA50	47.73%	Rel Volume	1.27	Prev Close	23.88
Employees	128	LT Debt/Eq	0.00	Earnings	Aug 12 AMC	SMA200	106.12%	Avg Volume	808.37K	Price	23.46
IPO	Jun 19, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	21.87% 55.05%	Trades		Volume	1,029,696	Change	-1.76%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-18-25	Initiated	Jefferies	Buy	$30
Dec-20-24	Initiated	Chardan Capital Markets	Buy	$24
Oct-14-24	Resumed	Leerink Partners	Outperform	$18
Mar-26-24	Upgrade	TD Cowen	Market Perform → Outperform
Nov-20-23	Resumed	JP Morgan	Neutral
Jul-25-23	Downgrade	TD Cowen	Outperform → Market Perform
May-01-23	Upgrade	BofA Securities	Underperform → Neutral	$9 → $12
Apr-26-23	Resumed	Canaccord Genuity	Buy	$24
Jan-06-23	Downgrade	BofA Securities	Buy → Underperform	$22 → $9
Oct-24-22	Upgrade	SVB Leerink	Mkt Perform → Outperform	$30
Jan-31-22	Initiated	Jefferies	Buy	$50
Dec-03-21	Initiated	BofA Securities	Buy	$43
Nov-22-21	Upgrade	JP Morgan	Neutral → Overweight	$41
May-18-21	Initiated	UBS	Neutral	$35
May-10-21	Upgrade	Wedbush	Neutral → Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform	$58
Feb-10-21	Downgrade	Wedbush	Outperform → Neutral
Dec-15-20	Resumed	H.C. Wainwright	Buy	$70
Dec-11-20	Reiterated	Needham	Buy	$48 → $56
Oct-23-20	Initiated	Cantor Fitzgerald	Overweight	$49

Show Previous Ratings

Sep-05-25 04:16PM	ZoomInfo, International Money Express, and More Stocks See Action From Activist Investors (Barrons.com) +5.35% +6.33%
Sep-02-25 07:00AM	Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome (Business Wire)
Aug-28-25 04:30PM	Stoke Therapeutics to Present at Upcoming Investor Conferences in September 2025 (Business Wire)
Aug-25-25 07:00AM	Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress (Business Wire)
Aug-18-25 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
03:12AM	Loading…
Aug-13-25 03:12AM	Stoke Therapeutics Inc (STOK) Q2 2025 Earnings Call Highlights: Strong Growth and Strategic ... (GuruFocus.com) +24.98%
Aug-12-25 05:10PM	Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
06:38AM	First patient dosed in Phase III trial of zorevunersen for Dravet syndrome (Clinical Trials Arena)
Aug-11-25 09:26AM	Stoke Therapeutics Inc (STOK) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
07:00AM	Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome (Business Wire)
07:00AM	Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome (GlobeNewswire)
Aug-07-25 07:00AM	Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates (Business Wire)
Aug-06-25 04:30PM	Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference (Business Wire)
Aug-05-25 06:35PM	Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
10:00AM	Loading…
Jul-30-25 10:00AM	Analysts Estimate Stoke Therapeutics, Inc. (STOK) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-18-25 10:17AM	Jefferies starts Stoke at Buy, sees $1 bln+ opportunity in rare epilepsy drug (Investing.com) +7.04%
Jul-16-25 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-10-25 07:00AM	Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress (Business Wire)
07:00AM	Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress (GlobeNewswire)
Jun-17-25 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-29-25 07:30AM	Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-16-25 09:55AM	Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet (Zacks)
May-13-25 09:50AM	Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates (Zacks) -7.56%
07:00AM	Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
May-12-25 06:33AM	Doximity Q4 Earnings Likely to Reflect Strong Product Momentum (Zacks)
May-01-25 12:44PM	BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance Cut (Zacks)
10:01AM	CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
09:28AM	Is Biogen At The 'Start Of A Turnaround' On Its Quarterly Beat? (Investor's Business Daily)
06:45AM	Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar (Investor's Business Daily)
10:00AM	Loading…
Apr-28-25 10:00AM	Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-24-25 06:53AM	Can Biogen Keep the Beat Streak Alive This Earnings Season? (Zacks)
Apr-22-25 12:00PM	Stoke Therapeutics (STOK) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +7.08%
04:00AM	Stoke Therapeutics (STOK) Soars 12.0%: Is Further Upside Left in the Stock? (Zacks)
Apr-01-25 04:30PM	Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference (Business Wire) -6.32% +5.94%
Mar-18-25 12:40PM	Stoke Therapeutics Stock Slips as CEO Steps Down (Investopedia)
12:40PM	Stoke Therapeutics Slips as CEO Steps Down (Investopedia)
08:05AM	Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:05AM	Stoke CEO exits; Medicare drug price talks advance (BioPharma Dive)
07:00AM	Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (Business Wire)
06:58AM	Stoke Therapeutics Announces CEO Transition (Business Wire)
Mar-17-25 10:00AM	Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-26-25 04:30PM	Stoke Therapeutics to Present at Upcoming Investor Conferences in March (Business Wire)
Feb-19-25 06:55AM	Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment (Pharmaceutical Technology)
Feb-18-25 01:32PM	Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal (Benzinga) -9.08%
08:00AM	Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments (Business Wire)
07:25AM	Biogen buys rights to Stokes rare epilepsy drug (BioPharma Dive)
Feb-05-25 08:51AM	Strength Seen in Stoke Therapeutics (STOK): Can Its 9.4% Jump Turn into More Strength? (Zacks)
Jan-08-25 04:30PM	Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
06:31AM	Tenvie raises $200M for brain drug R&D; Sana spikes on single patients results (BioPharma Dive)
Jan-07-25 07:00AM	Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome (Business Wire) -15.52%
Jan-06-25 04:30PM	Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome (Business Wire)
Dec-06-24 12:00PM	Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome (Business Wire) +5.57%
Dec-05-24 08:30AM	GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners (Business Wire)
Dec-04-24 07:00AM	Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome (Business Wire) +12.07%
Dec-02-24 08:00AM	Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting (Business Wire)
Nov-26-24 01:56AM	An RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond (Pharma Voice)
Nov-20-24 09:55AM	Stoke Therapeutics (STOK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-08-24 09:55AM	Wall Street Analysts Believe Stoke Therapeutics (STOK) Could Rally 66.84%: Here's is How to Trade (Zacks)
Nov-05-24 08:15AM	Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates (Business Wire)
Oct-29-24 10:01AM	Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-12-24 06:10PM	Stoke Therapeutics assumed with an Outperform at Leerink (TipRanks)
10:18AM	Stoke Therapeutics, Inc (STOK): Pioneering RNA Medicine for Genetic Diseases (Insider Monkey)
Sep-23-24 07:07PM	Skorpios Trust Reduces Stake in Stoke Therapeutics Inc (GuruFocus.com)
Sep-10-24 07:00AM	Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome (Business Wire)
Sep-04-24 08:00AM	Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer (Business Wire)
Sep-03-24 08:00AM	Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome (Business Wire)
08:00AM	Stoke Therapeutics to Present at Upcoming Investor Conferences in September (Business Wire)
Aug-16-24 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Aug-08-24 06:53AM	Stoke Therapeutics eyes Phase III Dravet syndrome trial, as FDA releases hold (Clinical Trials Arena)
Aug-07-24 08:25AM	Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates (Business Wire)
Jul-16-24 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) -7.19%
Jun-18-24 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Jun-13-24 09:00AM	The Lustgarten Foundation Appoints Two New Board Members (PR Newswire)
Jun-03-24 04:30PM	Stoke Therapeutics to Present at Upcoming Investor Conferences in June (Business Wire) +5.88%
May-22-24 07:07PM	Insider Sale: CEO Edward M. Kaye of Stoke Therapeutics Inc (STOK) Sells 42,350 Shares (GuruFocus.com) -6.96%
May-17-24 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) +15.83%
May-07-24 09:04PM	Stoke Therapeutics Inc (STOK) Reports Q1 2024 Financial Results: A Closer Look at Challenges ... (GuruFocus.com)
10:30AM	Canaccord Genuity Adjusts Price Target on Stoke Therapeutics to $20 From $21, Maintains Buy Rating (MT Newswires)
May-06-24 11:53AM	STOK Stock Earnings: Stoke Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:05AM	Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates (Business Wire)
Apr-29-24 10:21AM	Stoke Therapeutics Appoints Thomas Leggett CFO (MT Newswires)
08:00AM	Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer (Business Wire)
Apr-25-24 10:01AM	Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline (Zacks)
Apr-23-24 07:45AM	Garry Menzel joins GHO Capital as Operating Partner (GlobeNewswire)
Apr-17-24 08:00AM	Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer (Business Wire) -5.86%
Apr-04-24 04:30PM	Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference (Business Wire) -5.03%
Mar-27-24 11:40PM	Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering (Business Wire) +37.71%
08:50AM	Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data (Zacks)
Mar-26-24 04:07PM	Stoke Therapeutics Announces Proposed Public Offering (Business Wire) +58.31%
11:20AM	Stoke Therapeutics' Anti-Epilepsy Drug Candidate Shows Substantial, Sustained Reductions In Seizure Frequency In Pretreated Patients (Benzinga)
07:54AM	Why Is Stoke Therapeutics (STOK) Stock Up 99% Today? (InvestorPlace)
07:49AM	Stoke shares surge on updated results for Dravet drug (BioPharma Dive)
Mar-25-24 09:53PM	STOK Stock Earnings: Stoke Therapeutics Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
05:10PM	Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
04:01PM	Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome (Business Wire)

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ticho Barry	CHIEF MEDICAL OFFICER	Sep 02 '25	Sale	19.87	5,501	109,325	18,469	Sep 03 05:53 PM
Kaye Edward M. MD	Director	Sep 03 '25	Sale	20.13	45,996	925,858	91,585	Sep 03 05:51 PM
Kaye Edward M. MD	Director	Sep 02 '25	Sale	20.14	14,860	299,260	137,581	Sep 03 05:51 PM
Kaye Edward M. MD	Director	Aug 29 '25	Sale	20.00	1,029	20,580	152,441	Sep 03 05:51 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Sep 02 '25	Option Exercise	7.07	9,150	64,690	33,098	Sep 03 05:50 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Aug 29 '25	Option Exercise	7.07	850	6,010	24,798	Sep 03 05:50 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Sep 02 '25	Sale	20.14	14,922	300,492	18,176	Sep 03 05:50 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Sep 03 '25	Sale	20.07	6,345	127,317	11,831	Sep 03 05:50 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Aug 29 '25	Sale	20.00	850	17,000	23,948	Sep 03 05:50 PM
BARUCH TICHO	Officer	Sep 02 '25	Proposed Sale	19.76	10,844	214,277		Sep 02 04:37 PM
EDWARD M KAYE	Director	Aug 29 '25	Proposed Sale	19.77	61,885	1,223,466		Aug 29 04:17 PM
JONATHAN ALLAN	Officer	Aug 29 '25	Proposed Sale	19.77	22,117	437,253		Aug 29 04:17 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Aug 18 '25	Sale	18.24	2,805	51,158	23,970	Aug 20 04:13 PM
Kaye Edward M. MD	Director	Aug 18 '25	Sale	18.24	12,126	221,154	153,470	Aug 20 04:12 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Aug 18 '25	Sale	18.24	1,683	30,695	23,948	Aug 20 04:11 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Aug 14 '25	Option Exercise	0.00	10,000	0	26,775	Aug 18 08:25 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Aug 14 '25	Option Exercise	0.00	6,000	0	25,631	Aug 18 08:24 PM
Kaye Edward M. MD	Director	Aug 14 '25	Option Exercise	0.00	26,250	0	165,596	Aug 18 08:23 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Aug 13 '25	Sale	15.00	13,712	205,680	19,631	Aug 15 04:31 PM
JONATHAN ALLAN	Officer	Aug 13 '25	Proposed Sale	13.53	13,712	185,523		Aug 13 04:29 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Aug 01 '25	Sale	12.82	4,504	57,724	16,775	Aug 05 04:05 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Jul 01 '25	Sale	11.63	4,503	52,379	21,279	Jul 02 04:09 PM
LEVIN ARTHUR A	Director	Jun 30 '25	Option Exercise	0.00	1,210	0	2,420	Jul 02 04:08 PM
BARUCH TICHO	Officer	Jul 01 '25	Proposed Sale	11.35	9,007	102,229		Jul 01 04:27 PM
Skorpios Trust	10% Owner	Jun 04 '25	Sale	10.20	3,000,000	30,600,000	3,906,181	Jun 06 04:20 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Jun 03 '25	Sale	10.03	6,471	64,892	25,782	Jun 04 08:30 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Jun 02 '25	Sale	10.00	1,745	17,450	32,253	Jun 04 08:30 PM
Ticho Barry	CHIEF MEDICAL OFFICER	May 02 '25	Sale	10.03	22,790	228,543	33,998	May 05 04:08 PM
Ticho Barry	CHIEF MEDICAL OFFICER	May 01 '25	Sale	10.00	3,841	38,410	56,788	May 05 04:08 PM
BARUCH S. TICHO	Officer	May 01 '25	Proposed Sale	9.76	34,847	340,107		May 01 04:45 PM
LEVIN ARTHUR A	Director	Mar 31 '25	Option Exercise	0.00	1,210	0	1,210	Apr 02 04:03 PM
Kaye Edward M. MD	Director	Mar 18 '25	Sale	8.67	10,382	90,012	148,253	Mar 20 06:15 PM
Kaye Edward M. MD	Director	Mar 19 '25	Sale	8.27	8,907	73,661	139,346	Mar 20 06:15 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 18 '25	Sale	8.67	3,884	33,674	63,962	Mar 20 06:12 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 19 '25	Sale	8.27	3,333	27,564	60,629	Mar 20 06:12 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Mar 18 '25	Sale	8.67	2,266	19,646	33,510	Mar 20 06:05 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Mar 19 '25	Sale	8.27	1,945	16,085	31,565	Mar 20 06:05 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Mar 15 '25	Option Exercise	0.00	13,475	0	35,776	Mar 18 04:11 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 15 '25	Option Exercise	0.00	23,100	0	67,846	Mar 18 04:08 PM
Kaye Edward M. MD	CEO	Mar 15 '25	Option Exercise	0.00	61,750	0	158,635	Mar 18 04:07 PM
Kaye Edward M. MD	CEO	Dec 30 '24	Option Exercise	0.60	35,000	21,000	96,885	Jan 02 04:14 PM
Skorpios Trust	10% Owner	Dec 23 '24	Sale	11.50	2,000,000	23,000,000	6,906,181	Dec 27 05:13 PM
Blue Horizon Enterprise Ltd	Affiliate	Dec 23 '24	Proposed Sale	11.59	2,000,000	23,180,000		Dec 23 06:15 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Dec 09 '24	Sale	12.99	2,586	33,596	44,746	Dec 11 04:07 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Dec 09 '24	Sale	13.61	13,666	185,978	21,476	Dec 11 04:05 PM
Kaye Edward M. MD	CEO	Dec 09 '24	Sale	12.99	6,786	88,158	61,885	Dec 11 04:04 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Dec 06 '24	Sale	12.78	13,945	178,182	47,332	Dec 10 07:02 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Dec 06 '24	Sale	12.78	9,696	123,891	35,142	Dec 10 07:01 PM
Kaye Edward M. MD	CEO	Dec 06 '24	Sale	12.78	6,170	78,837	68,671	Dec 10 07:00 PM
JONATHAN ALLAN	Officer	Dec 09 '24	Proposed Sale	13.27	12,114	160,753		Dec 09 04:48 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Dec 03 '24	Option Exercise	0.00	6,000	0	44,838	Dec 05 04:21 PM
Kaye Edward M. MD	CEO	Dec 03 '24	Option Exercise	0.00	26,500	0	75,091	Dec 05 04:20 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Dec 03 '24	Option Exercise	0.00	10,000	0	61,277	Dec 05 04:19 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Dec 01 '24	Option Exercise	0.00	33,927	0	38,838	Dec 03 04:14 PM
Kaye Edward M. MD	CEO	Dec 01 '24	Option Exercise	0.00	21,591	0	48,591	Dec 03 04:13 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Dec 02 '24	Option Exercise	0.60	10,000	6,000	61,277	Dec 03 04:11 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Dec 01 '24	Option Exercise	0.00	48,792	0	51,277	Dec 03 04:11 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Dec 02 '24	Sale	12.07	10,000	120,698	51,277	Dec 03 04:11 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Nov 01 '24	Option Exercise	0.60	10,000	6,000	12,485	Nov 05 04:15 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Nov 01 '24	Sale	12.68	10,000	126,803	2,485	Nov 05 04:15 PM
BARUCH TICHO	Officer	Nov 01 '24	Proposed Sale	12.36	20,000	247,200		Nov 01 04:50 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Oct 01 '24	Option Exercise	0.60	10,000	6,000	12,485	Oct 02 04:07 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Oct 01 '24	Sale	12.06	10,000	120,648	2,485	Oct 02 04:07 PM
Skorpios Trust	10% Owner	Sep 19 '24	Sale	14.05	1,937,500	27,221,875	8,906,181	Sep 23 04:23 PM
Blue Horizon E LTD	Affiliate	Sep 19 '24	Proposed Sale	15.22	1,937,500	29,488,750		Sep 19 05:23 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

STOK

Stoke Therapeutics Inc

Upgrade your FINVIZ experience